Tümay studied Biotechnology at the University of Natural Resources and Life Sciences (BOKU) in Vienna. For his master thesis he worked on a high-throughput method for protein complex localization assignment at ETH Zurich. In October 2020 he joined the Huber group as a PhD student to work on the development of new statistical and machine-learning methods for the analysis of multi-omics data.
Sarah completed her PhD in Biology at Heidelberg University, where she developed mathematical models for gene expression in bacteria. Her role at EMBL is shared between the Huber group and Bio-IT (Center for Statistical Data Analysis). She will support EMBL’s scientific community in statistical data analysis by providing consulting and courses.
Alexandra obtained her BSc degree in Molecular Biotechnology from the University of Heidelberg. She wrote her Bachelor thesis at the Center for Molecular Biology of Heidelberg University (ZMBH) and is currently enrolled in the Molecular Biotechnology Master’s program of the University of Heidelberg. She joined the Huber group as a trainee in May 2020 and is working on viral sequence data in order to understand adaptive immune responses to viral infections.
Alex received his PhD in theoretical particle physics from the University of Heidelberg and the Max Planck Institute for Nuclear Physics before he joined the Huber group as postdoc fellow in February 2020. As a member of the DECODE project, his current research focuses on single-cell analyses and the development of statistical methods for biological data.
Alina has a BSc degree in Molecular Biotechnology from the University of Heidelberg. She wrote her Bachelor thesis at the Max-Planck-Institute (MPI) for Medical Research and is currently enrolled in the Molecular Biotechnology Masters program. After a research internship at the University of Queensland and an internship in the non-academic sector, Alina joined the Huber Group in January 2020. She is working on the integrative analysis of drug testing data in order to understand the mechanisms of drug response.
We are continually inviting applications for postdoc, PhD and internship positions. You can apply for one of two tracks:
- Method development in statistical computing and bioinformatics,
- Biological discovery through integrative data analysis (“dry biology”)
For track 1, you will have strong quantitative and analytical skills, such as acquired through a degree in mathematics, statistics, physics, computer science or a related field. You have curiosity and motivation to work in interdisciplinary projects, which include generation of new data and their analysis, and are eager to get to grips with relevant areas of biology and the technologies used in biology research. You will have experience in scientific computing and be familiar with one or several computer languages. Familiarity with R is definitively a plus.
For track 2, you will have a training in life sciences and strong coding skills that enable you to undertake complex data transformations, integrative operations, applications of mathematical models and visualizations. You are driven by making fundamental discoveries by mining cutting-edge, large data sets.
To apply, please contact Wolfgang with your CV, a brief statement of research interests, and examples of your work: besides your publications, this can include theses, research reports, talk slides, software projects (e.g. R packages, github projects) or data analysis reports (e.g. markdown reports or Jupyter notebooks).
Please note that we recruit PhD candidates via EMBL’s international PhD programme and you need to submit your application documents within the deadline, even if you have discussed the PhD position with Wolfgang Huber in advance.
Here are some keywords and a non-exhaustive list of collaboration partners with whom we work frequently on new, exciting data types:
- Latent spaces and manifolds estimation from multi-modal single cell data
- Genotype-drug interactions, precision oncology, multivariate biomarker discovery
- Imaging-based phenotyping
- Thorsten Zenz – pharmacogenomics of drug response in blood cancer
- Sascha Dietrich – systems medicine of cancer drugs
- Lars Steinmetz – systems genetics & ‘omics technology development
- Michael Boutros – high-throughput genetics, genetic interactions & synthetic lethality in cancer
- Henrik Kaessmann – evolution of cell types
Holly Giles was awarded the Joachim-Herz Add-On Fellowship for Interdisciplinary Science. The fellowship enables interdisciplinary research and qualification (e.g. stays at a research lab and participation in conferences), specialized equipment and tools (laptops, software, etc.), participation in events of the Joachim Herz Foundation and fellowship meetings. Its a € 12.500 grant to be spent over a period of two years.
Dorothee Childs, Karsten Bach, Holger Franken, Simon Anders, Nils Kurzawa, Marcus Bantscheff, Mikhail Savitski and Wolfgang Huber
Detecting the targets of drugs and other molecules in intact cellular contexts is a major objective in drug discovery and in biology more broadly. Thermal proteome profiling (TPP) pursues this aim at proteome-wide scale by inferring target engagement from its effects on temperature-dependent protein denaturation. However, a key challenge of TPP is the statistical analysis of the measured melting curves with controlled false discovery rates at high proteome coverage and detection power. We present non-parametric analysis of response curves (NPARC), a statistical method for TPP based on functional data analysis and nonlinear regression. We evaluate NPARC on five independent TPP datasets and observe that it is able to detect subtle changes in any region of the melting curves, reliably detects the known targets, and outperforms a melting point-centric, single-parameter fitting approach in terms of specificity and sensitivity. NPARC can be combined with established analysis of variance (ANOVA) statistics and enables flexible, factorial experimental designs and replication levels. To facilitate access to a wide range of users, a freely available software implementation of NPARC is provided.
Arne H. Smits, Frederik Ziebell, Gerard Joberty, …, Lars M. Steinmetz, Gerard Drewes and Wolfgang Huber.
Gene knockouts (KOs) are efficiently engineered through CRISPR-Cas9-induced frameshift mutations. While DNA editing efficiency is readily verified by DNA sequencing, a systematic understanding of the efficiency of protein elimination has been lacking. Here, we devised an experimental strategy combining RNA-seq and triple-stage mass spectrometry to characterize 193 genetically verified deletions targeting 136 distinct genes generated by CRISPR-induced frameshifts in HAP1 cells. We observed residual protein expression for about one third of the quantified targets, at variable levels from low to original, and identified two causal mechanisms, translation reinitiation leading to N-terminally truncated target proteins, or skipping of the edited exon leading to protein isoforms with internal sequence deletions. Detailed analysis of three truncated targets, BRD4, DNMT1 and NGLY1, revealed partial preservation of protein function. Our results imply that systematic characterization of residual protein expression or function in CRISPR-Cas9 generated KO lines is necessary for phenotype interpretation.
After completing his pharmacy studies at University College Cork and the Royal College of Surgeons in Ireland, Donnacha joined the Huber group in October 2019 for a joint PhD with the Dietrich group at the National Centre for Tumour Diseases in Heidelberg. His current research focuses on using single-cell multi-omics to understand intra-tumour heterogeneity of drug response in blood cancers.